AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 PAVmedSANUWAVE HealthBRAINSWAY LTD/SPro-DexNephros
SymbolNASDAQ:PAVMOTCMKTS:SNWVNASDAQ:BWAYNASDAQ:PDEXOTCMKTS:NEPH
Price Information
Current Price$2.22$0.27$7.29$19.95$7.90
52 Week RangeBuyN/ABuyN/ABuy
Beat the Market™ Rank
Overall Score1.20.71.30.81.8
Analysis Score3.50.03.50.03.5
Community Score2.62.82.32.32.0
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.01.03.0
Earnings & Valuation Score0.00.60.60.60.6
Analyst Ratings
Consensus RecommendationBuyN/ABuyN/ABuy
Consensus Price Target$5.00N/A$11.00N/A$16.00
% Upside from Price Target125.23% upsideN/A50.87% upsideN/A102.53% upside
Trade Information
Market Cap$92.92 million$82.13 million$84.40 million$76.29 million$69.08 million
Beta-0.02-0.730.911.20.85
Average Volume1,179,438354,52210,61015,87516,362
Sales & Book Value
Annual RevenueN/A$1.03 million$23.10 million$27.17 million$5.69 million
Price / SalesN/A79.453.422.8412.51
CashflowN/AN/AN/A$1.13 per shareN/A
Price / CashN/AN/AN/A17.64N/A
Book Value($0.18) per share($0.03) per share$2.24 per share$4.14 per share$0.89 per share
Price / BookN/A-9.133.254.828.88
Profitability
Net Income$-16,460,000.00$-10,430,000.00$-10,330,000.00$4.15 million$-3,400,000.00
EPSN/AN/A($0.50)N/A($0.54)
Trailing P/E RatioN/A0.00N/A18.30N/A
Forward P/E RatioN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-1,122.95%-44.71%14.50%-49.93%
Return on Equity (ROE)N/AN/A-48.90%25.64%-56.37%
Return on Assets (ROA)-191.38%-465.37%-28.03%16.13%-35.17%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.20%0.26%
Current Ratio0.36%0.17%4.29%4.64%2.56%
Quick Ratio0.36%0.13%4.29%2.69%1.86%
Ownership Information
Institutional Ownership Percentage7.32%0.38%17.37%13.38%N/A
Insider Ownership Percentage34.40%23.40%N/A38.60%6.80%
Miscellaneous
Employees914968018
Shares Outstanding46.93 million298.66 million10.82 million3.87 million9.01 million
Next Earnings Date8/12/2020 (Estimated)8/20/2020 (Estimated)6/3/2020 (Estimated)9/3/2020 (Estimated)N/A
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.